Immunotherapy Revolutionizing Gynecologic Cancers: Progress and Challenges
*Corresponding Author: Dr. Natasha Evans, Memorial Sloan Kettering Cancer Center, USA, Email: natasha.evans@hotmail.comReceived Date: Jun 04, 2025 / Published Date: Jun 30, 2025
Citation: Evans DN (2025) Immunotherapy Revolutionizing Gynecologic Cancers: Progress and Challenges. Current Trends Gynecol Oncol 10: 280
Copyright: 漏 2025 Dr. Natasha Evans This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
| Peer-reviewed Full Article 
Abstract
Immunotherapy, especially immune checkpoint inhibitors (ICIs), is rapidly transforming gynecologic oncology, demonstrating efficacy in advanced ovarian, cervical, and endometrial cancers. Pembrolizumab has become a standard of care for specific advanced cervical cancers and dMMR/MSI-H endometrial cancers. Challenges include biomarker identification, resistance mechanisms, and tumor microenvironment modulation. Novel targets, gut microbiome influence, and CAR T-cell therapy are under investigation. Safe management of immune-related adverse events is essential. Personalized immunotherapy strategies are a key focus.
